DOI: http://dx.doi.org/10.18203/issn.2454-5929.ijohns20221057

Prevalence of hypokalemia in a patients of post COVID-19 mucormycosis receiving injection liposomal-amphotericin B at tertiary care hospital

Kavita Sachdeva, Mayur V. Kabade, Amrita Shukla, Anjalikrishna B., Lakshmy V. Raj, Stephy Maria Tom

Abstract


Background: Hypokalemia is one of the most common electrolyte disturbances seen in clinical practice and in patients receiving liposomal-amphotericin B (L-AMB). The aim of this retrospective study was to examine the prevalence of hypokalemia in patients of post COVID-19 mucormycosis receiving L-AMB and to evaluate common presenting symptoms of hypokalemia in them.

Methods: The present study was conducted as a retrospective study on 100 patients of post COVID-19 mucormycosis who received L-AMB for 1st time between May 2021 and August 2021 at department of otorhinolaryngology and head and neck surgery, Netaji Subhash Chandra Bose medical college and hospital, Jabalpur, Madhya Pradesh, India.                                                                                                                  

Results: In the present study, hypokalemia of varying grades occurred in 23% of the patients, making it an adverse event that requires attention and correction. Hypokalemia is reported in middle aged adults, more in males compared to females and at doses less than 2 gm of L-AMB. Majority (91.30%) of the patients of mucormycosis who developed hypokalemia presented with generalized weakness, anorexia and muscle cramps followed by nausea which is seen in 82.60% patients. Constipation, bloating and abdominal pain being other presenting symptoms in them seen in 56.50%, 56.50% and 52.20% patients respectively.

Conclusions: Hypokalemia is a common electrolyte disorder occurring in patients receiving L-AMB which if undetected can be life threatening. Adequate medical management of these patients not only requires proper antifungal administration but also management of electrolyte imbalances related to the administration. L-AMB is a life-saving drug provided it is used judicially and with utmost care.

 


Keywords


Post COVID-19 mucormycosis, L-AMB, Hypokalemia, Hypomagnesemia

Full Text:

PDF

References


Mucormycosis. Available at: https://www.who.int/ india/emergencies/coronavirus-disease-(covid-19)/mucormycosis. Accessed on 10 December 2021.

Singh AK, Singh R, Joshi SR, Misrac A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-21.

Stone NR, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome (®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs. 2016;76(4):485-500.

Yamazaki H, Kondo T, Aoki K, Yamashita K, Takaori-Kondo A. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis. Diagn Microbiol Infect Dis. 2018;90(2):123-31.

Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. Hypokalemia: a clinical update. Endocrine connections. 2018;7(4):R135-46.

Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-71.

Kuse ER, Chetchotisakd P, Da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet. 2007;369:1519-27.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15.

Nichols AJ, Koster PF, Brooks DP, Ruffolo RR. Effect of fenoldpam on acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther. 1992;260:269-74.

Tasset C, Preat V, Bernard A, Roland M. Comparison of nephrotoxicities of different polyoxyethylenglycol formulations of amphotericin B in rats. Antimicrob Agents Chemother. 1992;36:1525-31.

Sabra R, Branch RA. Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob Agents Chemother. 1991;35(12):2509-14.

Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6(2):154-64.

Steinmetz PR, Lawson LR. Defect in urinary acidification induced in vitro by amphotericin B. The Journal of Clinical Investigation. 1970 Mar;49(3):596-601.

Yamazaki H, Kondo T, Aoki K, Yamashita K, Takaori-Kondo A. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis. Diagn Microbiol Infect Dis. 2018;90(2):123-31.

Ringden O, Andström E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone marrow transplantation. 1994;14:S10-4.

Sunakawa K, Tsukimoto I, Tsunematsu Y, Honda M, Iwai N, Suzuki K, et al. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children. J Infect Chemotherapy. 2012;18(4):456-65.

Coca SG, Perazella MA, Buller GK. The cardiovascular implications of hypokalemia. Am J Kidney Dis. 2005;45(2):233-47.

Patel GP, Crank CW, Leikin JB. An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB). J Med Toxicol. 2011;7(1):12-5.

Rocha PN, Kobayashi CD, de Carvalho Almeida L, de Oliveira Dos Reis C, Santos BM, Glesby MJ. Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria. Antimicrob Agents Chemother. 2015;59(8):4759-69.

Cornely OA, Maertens J, Bresnik M. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-97.

Ueda S, Miyamoto S, Kaida K. Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65 years old with hematological diseases. J Infect Chemother. 2016;22(5):287-91.

Marino PL, Kenneth M. The ICU book Sutin-3rd Edition-Chapter 33 and 34-Potassium and Magnesium. 2017;639-71.